|

Adagrasib Clinical Trials

7 actively recruiting trials across 7 locations

Also known as: BMS-986503; KRAZATI®, Krazati, MRTX849, Pembrolizumab, Pemrolizumab

Birmingham, Alabama1 trial

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3

Goodyear, Arizona1 trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-556-A

Phase 2/3

Phoenix, Arizona1 trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1

Santa Rosa, California1 trial

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Local Institution - 101

Phase 2

Boston, Massachusetts1 trial

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2

Columbus, Ohio1 trial

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Ohio State University Comprehensive Cancer Center

Phase 2

Houston, Texas1 trial

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

M D Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.